23.35 0.00 (0.00%)
After hours: 4:35PM EDT
|Bid||16.50 x 1400|
|Ask||24.75 x 38800|
|Day's Range||23.20 - 23.55|
|52 Week Range||11.85 - 23.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In the North America region, Teva registered Copaxone sales of $476 million, representing a YoY (year-over-year) decline of 40% due to increased competition from generics in the United States where the Copaxone sales were $462 million in fiscal 1Q18. In Europe, Copaxone sales registered growth of ~1% to $153 million. In the Growth Market segment, Copaxone sales came in at $16 million, a YoY decline of 24%.
Westphal has a long track record of co-founding successful drug developers, including Alnylam Pharmaceuticals and Momenta Pharmaceuticals.
Momenta Pharmaceuticals Inc’s (NASDAQ:MNTA): Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. TheRead More...
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 31. Over the last one-month, outflows of investor capital in ETFs holding MNTA totaled $1.01 billion.
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 31. Over the last one-month, outflows of investor capital in ETFs holding MNTA totaled $237 million.
The Street has long been ambivalent on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA )'s prospects. But the generic drug developer scored one new advocate Thursday on the basis of its pipeline potential. ...
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 18 cents. The biotechnology company posted revenue of $64.6 million in the period. For the year, the company reported ...
This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.